DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

Dawnrays Pharmaceutical (Holdings) Limited

2348

KYG2687M1006

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:34 21/06/2024 BST			5-day change	1st Jan Change
1.18 ^HKD	-2.48%		0.00%	+12.38%

05-24	Dawnrays Pharmaceutical Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023	CI
03-26	Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024	CI

Dawnrays Pharmaceutical Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023

May 24, 2024 at 10:47 am

Dawnrays Pharmaceutical (Holdings) Limited at its AGM held on May 24, 2024 approved To declare a final dividend of HKD 0.065 per share for the year ended 31 December 2023.

Latest news about Dawnrays Pharmaceutical (Holdings) Limited

Dawnrays Pharmaceutical Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2023	05-24	CI
Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024	03-26	CI
Dawnrays' 2023 Profit Falls 9% on Lower Revenue	03-25	MT
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	02-09	MT
Dawnrays Pharmaceutical Limited Declares Interim Dividend for the Year Ending December 31, 2023, Payable on October 5, 2023	25/08/23	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Dawnrays Pharmaceutical Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection	02/06/23	CI
Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2022	25/05/23	CI
Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 13 June 2023	26/03/23	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022	26/03/23	CI
Dawnrays Pharmaceutical Unit to Provide $14.4 Million Loan to AD Pharmaceuticals	25/10/22	MT
Dawnrays Pharmaceutical Limited(SEHK:2348) dropped from S&P Global BMI Index	19/09/22	CI
Dawnrays Pharmaceutical Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022	26/08/22	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2022	26/08/22	CI
Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended December 31, 2021	27/05/22	CI
Dawnrays Pharmaceutical Limited Proposes to Declare Final Dividend for the Year Ended December 31, 2021	21/04/22	CI
Dawnrays Pharmaceutical Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022	27/03/22	CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2021	27/03/22	CI
Dawnrays Pharma CEO Resigns	17/02/22	MT
Dawnrays Pharmaceutical Limited Announces Resignation of Chen Shaojun as Executive Director, Effective February 16, 2022	16/02/22	CI
Dawnrays Pharmaceutical Limited Announces Executive Changes	16/02/22	CI
Dawnrays Pharma Unit to Sell 35% Stake in Solvent Recovery Services Provider for Nearly $9 Million	27/01/22	MT
Dawnrays Pharmaceutical : Arm Seeks Marketing Nod for Injectable Products in China	24/09/21	MT
Tranche Update on Dawnrays Pharmaceutical Limited's Equity Buyback Plan announced on August 27, 2020.	15/09/21	CI

Chart Dawnrays Pharmaceutical (Holdings) Limited

Duration

Period

Chart Dawnrays Pharmaceutical (Holdings) Limited

More charts

Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED	+12.38%	227M
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B